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Abstract
Protease inhibitors (PIs) block HIV-1 maturation into an infectious virus particle by inhibiting the
protease processing of gag and gag-pol precursor proteins. We have used a simple anti-HIV-1 p24
Western blot to monitor the processing of p55gag  precursor into the mature p24 capsid
immediately following the first dosage of a PI-containing treatment regimen. Evidence of PI activity
was observed in plasma virus as early as 72 hours post treatment-initiation and was predictive of
plasma viral RNA decrease at 4 weeks.
Background
Assembly and transport of the 55 kDa gag (p55gag) and
160 gag-pol (p160gag-pol) proteins to the inner plasma
membrane is essential for the packaging of the viral
genomic RNA, host tRNALys,3 primer, as well as for inter-
actions with HIV-1 envelope glycoproteins [5]. Budding
and virus release initiates the processing of the gag and
gag-pol  precursor proteins. This processing step likely
requires the dimerization of two gag-pol  precursors (at
least in the region of protease) that permits a low-effi-
ciency cleavage of the precursor proteins and release of
fully active protease (PR) homodimers [16]. These
enzymes then complete protein maturation to produce an
infectious virus particle. Thus, protease inhibitors (PI)
appear to be most active at blocking HIV-1 replication fol-
lowing budding of the immature virus particle [4,6]. In
contrast other antiretroviral drugs (ARV) such as nucleo-
side reverse transcriptase inhibitors (NRTI) and non-nucl-
eoside RT inhibitors (NNRTI), block reverse transcription
during intracellular HIV-1 replication [3].
Published: 12 April 2005
AIDS Research and Therapy 2005, 2:2 doi:10.1186/1742-6405-2-2
Received: 28 February 2005
Accepted: 12 April 2005
This article is available from: http://www.aidsrestherapy.com/content/2/1/2
© 2005 Baird et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.AIDS Research and Therapy 2005, 2:2 http://www.aidsrestherapy.com/content/2/1/2
Page 2 of 8
(page number not for citation purposes)
To date, the best method to monitor inhibition of HIV-1
replication is to evaluate virus concentrations in the
plasma [10]. Several commercial, FDA-approved assay
kits (HIV-1 Quantiplex (bDNA) assay, AMPLICOR HIV-1
MONITOR assay, NucliSens HIV-1 assay) involve measur-
ing virus levels via reverse transcription-PCR amplifica-
tion of genomic HIV-1 RNA [8]. It is important to
recognize however, that these assays cannot monitor the
pharmacodynamic properties of many antiretroviral
agents immediately following treatment initiation. Pro-
tease inhibitors block HIV-1 protease processing follow-
ing virus release from cells in contrast to NNRTIs or NRTIs
that inhibit during an intracellular replication step, i.e.
reverse transcription. The half life of plasma virus is esti-
mated to be approximately 6 hrs [13,18]. but the half life
of activated CD4+ cells infected with and producing HIV
even in the presence of PIs is approximately 1.2 days
[13,18,19] during phase I decay An assay measuring levels
of viral RNA does not distinguish between the immature
virus (processing blocked by PIs) and infectious virus,
both of which encapsidate HIV-1 genomic RNA. The esti-
mated time required for protease inhibitors to clear the
majority of free virus particles from the circulation and
activated cells (not latently infected or quiescent cells) is
approximately 4 weeks. Thus, a viral RNA assay performed
on plasma does not provide a complete assessment of PI
activity for at least 1–4 weeks.
Methods
In this study, we tested the ability of three different assays
to measure the quantity of both infectious virions and
defective/immature virus particles in the plasma of HIV-
infected patients who started treatment with a PI-contain-
ing regimen. The performance of three assays was vali-
dated in vitro utilizing HIV-1 infected cell lines in the
presence or absence of PIs and other ARVs. These tests
were followed by in vivo analyses using plasma samples
from patients receiving a PI-based treatment regimen. The
following provides a brief summary of the first two assays
that could detect the effects of PI activity in vitro but failed
in vivo.
The first assay involved measurement of infectious virus
potential. We serially diluted cell-free culture superna-
tants from chronically HIV-infected U87.CD4.CCR5 cells
treated with PIs. This diluted and undiluted plasma was
then added to uninfected peripheral blood mononuclear
cells (PBMC). Although this assay could be used to meas-
ure infectious potential of high titer viruses in tissue cul-
ture, only plasma containing extremely high viral loads (>
104 viral RNA copies/ml) could support any HIV-1 infec-
tion of PHA/IL-2 treated PBMC regardless of the patients
treatment status (data not shown). Concentrating the
virus by ultracentrifugation did little to increase infectious
titer of virus from plasma.
The second assay involved PCR amplification of strong-
stop viral DNA found in cell-free virus. Previous reports
have shown that viral DNA is found HIV-1 particles [9,17]
but that steric hindrance or the lack of dNTP substrates
limit reverse transcription and presence of viral DNA to
1:1000 to 1:10,000 virions [1,2]. We have shown that a
defective protease abolishes the synthesis of any HIV-1
DNA in virus particles [1,2]. HIV-1 strong-stop DNA was
not detected by PCR amplification in virus produced from
the chronically infected cells in the presence of PIs (data
not shown). However, viral loads of >10,000 RNA copies/
ml were required in patients to even detect the presence of
HIV-1 DNA in plasma, which is consistent with previous
findings. Thus, this assay was not effective for those
patients starting PI therapy with lower viral loads (<103–4
RNA copies/ml).
In contrast to the assays described above, an anti-p24
Western blot was successful in measuring both in vitro
and in vivo PI effects and was the simplest in design and
application. To initially test this assay we infected
U87.CD4.CXCR4 cells with a wild type HXB2 virus or the
protease inhibitor resistant virus, RF (containing PR muta-
tions V82F and I84V) [12]. Following established infec-
tion and stable virus production over three days (as
measured by RT activity in the culture supernatant), cul-
tures were treated with 0.2 and 20 nM lopinavir (LPV) or
2 and 200 nM nevirapine (NVP). The higher concentra-
tion of each drug was approximately 100-fold greater than
the reported IC50 values (i.e. lower concentrations of each
drug) [11,14,15]. Cell free culture supernatant (1 ml) was
then harvested at 0, 4, 8, 24, and 72 h post drug addition.
Virus was pelleted from the supernatant by ultracentrifu-
gation (35,000 g for 1 h) and then resuspended in 50 µl
of sodium-dodecyl sulfate (SDS) lysis buffer (1% SDS,
10% glycerol, 10% β -mercaptoethanol, 0.04 M Tris pH
6.8); of which 10 µl were heated to 95°C, separated on
Tris-HCl-12.5% polyacrylamide precast gels (Bio-Rad),
and transferred onto polyvinylidene difluoride mem-
branes (Immobilon P; Millipore)by electroblotting (Bio-
Rad). Membranes were incubated with blocking reagent
(5% milk-0.05% Tween in phosphate-bufferedsaline) for
1 h at room temperature then hybridized with a mouse
anti-p24 monoclonal antibody (diluted 1:1,000; Fitzger-
ald Industries International, Inc.) overnight at 4°C. After
washing, membranes were incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG1 antiserum
(diluted 1:40,000; Pierce) for 3 hours. Immune com-
plexes were visualized with the ECL system (Amersham)
according to the manufacturer's instructions and films
were analyzed using BioRad Quantity One software.
Results and discussion
Fig. 1, panels A and B show Western blot analyses and
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(protease inhibitor resistant) and HXB2 (protease inhibi-
tor sensitive) and treated with 20 nM LPV. Two major
bands appeared on the film of the ECL blot. The faster
migrating product was the processed capsid (CA) p24 and
the slower migrating band was unprocessed p55gag. We
observed minute amounts of partly cleaved gag product
containing the matrix (MA) p17 and CA p24, i.e. 41 kDa.
In these experiments, the HXB2 p55:p24 is increasing over
the first 72 hours of 20 nM LPV treatment indicating an
inhibition of gag processing. In contrast, there was no evi-
dence of decreased gag precursor processing with the RF
virus treated with 20 nM LPV as indicated by a constant
p55:p24 ratio of 0.1 during the 72 h of treatment. Treat-
ment with a lower concentration of LPV (0.2 nM) or with
NVP (2 or 200 nM) did not result in a significant differ-
ence in the HXB2 or RF p55:p24 ratios over time (data not
shown). In tissue culture, longer incubation times with
LPV (20 nM) reduced virus production to levels at which
the quantities of p55 and p24 products were difficult to
detect by Western blot analyses.
Western blots for the HIV-1 gag proteins in HIV-1 produced in tissue culture following treatment with protease inhibitors Figure 1
Western blots for the HIV-1 gag proteins in HIV-1 produced in tissue culture following treatment with pro-
tease inhibitors. U87/CD4/CXCR4 cells were plated in 6 well plates at 80,000 cells/well and allowed to grow to confluence. 
The cells were infected with either HXB2 or RF/V82F/I84V (protease inhibitor resistant virus) and RT activity was monitored. 
On day 3 of culture, infected cells were treated with 20 nM LPV, and 1 ml of media was removed at 0, 4, 8, 24, and 72 hours 
post-drug treatment. The virus was pelleted, and the pellet was then lysed using sodium-dodecyl sulfate (SDS) lysis buffer and 
then run on a 10% SDS polyacrylamide gel. Following transfer to nylon membranes, blots were probed with the primary mouse 
anti-p24 antibody and the horseradish peroxidase-conjugated goat anti-mouseantiserum. Films were exposed following treat-
ment with the ECL kit (panel A). Ratio of unprocessed p55gag to processed CA p24 over a 72 hour time course was deter-
mined by scanning the blots and quantifying the bands (panel B).
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To test the utility of this simple Western blot assay to
monitor initial PI treatment, nine patients were enrolled
into the A5036s Substudy of the ACTG Clinical Trial
Substudy A5014 [7]. All of the patients in A5014 were
ARV treatment naïve and were randomized to receive
either LPV+ the non-nucleoside RT inhibitor NVP or NVP
+ three nucleoside RT inhibitors: lamivudine (3TC) + sta-
vudine (D4T) + abacavir (ABV). All participants and
investigators in this study were blinded to the treatment
arms. Ten ml of blood was drawn into Acid Citrate Dex-
trose (ACD) tubes prior to the first drug administration,
then 4, 8, 12, 24, 72 hours, three days and four weeks post
drug administration. Two aliquots of 3.5 ml of plasma
were shipped on dry ice to CWRU and then stored at -
70°C prior to analyses.
In addition to the Western blot analyses, the sub-study
also called for a measure of infectious potential by HIV-1
found in plasma. For these tests we exposed HIV-negative
peripheral blood mononuclear cells to plasma samples
obtained prior to and immediately following treatment
with the PI- or non PI-containing HAART regimen. Only
plasma samples of one patient (of 9) resulted in produc-
tive infection of PHA/IL-2 treated PBMC cultures suggest-
ing that this not a sensitive assay. Unfortunately, no
assessment of PI activity could be evaluated using this
infectious assay since this patient was treated with NVP
and the three NRTIs. It is unlikely that viral levels in
plasma is the sole factor contributing to the ability of
plasma virus to infect PBMC cultures since all patients in
this substudy had viral RNA loads approximately 104 cop-
ies/ml at initiation of treatment. The level of virus produc-
tion or success of PBMC infections did not increase if the
virus was concentrated from plasma by ultracentrifuga-
tion. This concentration step would also remove any
residual drug in plasma that might affect infectivity of
virus in plasma after the initial treatment.
Preliminary data indicated that plasma protein concentra-
tions were too high to efficiently concentrate virus and
resulted in excessive background on the Western blot for
HIV-1 gag proteins. Thus, 1.5 ml of each plasma sample
was diluted with 3.5 ml of phosphate-buffered saline
(PBS) prior to concentrating the virus by ultracentrifuga-
tion. The procedures for the Western blot analyses are
described above. Fig. 2A shows the Western blot results
employing samples from patients A and B from the
ACTG5014 clinical trial. It is important to note that this
was a double-blinded trial and that all samples from each
patient were analyzed prior to knowledge of treatment
regimens [7]. Interestingly, the ratio of p55:p24 was
greater than 1 in 8 of 9 patient samples prior to ARV treat-
ment. High p55:p24 ratios suggest an increased propor-
tion of noninfectious virus particles to infectious virions
in the plasma. The ratio of p55:p24 in HIV-1 propagated
in tissue culture is typically much less than one, suggestive
of higher proportions of infectious to non-infectious virus
in plasma. Most plasma proteins or free viral proteins
were separated from the virus via centrifugation and pel-
leting of the virus. A 95% reduction of Coomassie blue
staining of all proteins on the SDS PAG following transfer
suggested that both the p55 and p24 proteins were effi-
ciently electrotransferred to the nylon membranes.
Increased ratios of p55:p24 was not due to selective anti-
body binding to the p55gag considering the anti-p24 anti-
body should bind at least as efficiently to CA p24 than to
the unprocessed p55gag. It is also possible that background
p55 is due to the rapid turnover, and therefore that nas-
cent virions make up a large fraction of the total. These vir-
ions could be more infectious than the fully processed
ones seen in cell culture, since they would be rapidly proc-
essed in the course of the assay.
We predicted that the p55:p24 ratio would increase dur-
ing first three days of PI treatment with the possible dips
in this ratio between PI dosages (every 12 h). Preliminary
data with patients starting a PI-containing treatment regi-
men suggest a PI-mediated inhibition of p55 processing
within 8–12 h of treatment (data not shown). However,
these studies were performed with patients starting
RIT+SAQ or IND-containing treatment regimens and not
with patients treated with LPV. As indicated by the results
of tissue culture infection experiments shown in Fig. 1, the
p55:p24 ratio should remain stable in plasma samples
obtained from patients receiving non-PI containing
HAART regimens (i.e. NVP+3TC+D4T+ABV) since neither
NRTI nor NNRTI inhibit processing of the gag or gag-pol
precursors.
Although only one example of these analyses is shown
(Fig. 2B, panel I and II), the Western blot results of plas-
mas from each of four patients treated with the
NVP+3TC+D4T+ABV combination showed a constant
ratio of p55:p24 following treatment. In patients rand-
omized to receive the LPV+NVP regimen, the ratio of
p55:p24 increased at 72 h following the initial dosing
(Fig. 2B). This increase in the p55:p24 ratio was main-
tained after 4 weeks of PI treatment. Previous findings
revealed that HAART resulted in a drop in RNA and
plasma infectivity in one day [20], however, the efficacy of
ARV treatment can be affected by factors such as drug con-
centrations, compliance, potency, and selection of ARV
resistant quasispecies. Unfortunately, two of the patients
randomized to receive the LPV+NVP combination
dropped out of the 5036 sub-study prior to the 72 h sam-
ple collection, i.e. the time that is likely required to detect
a LPV block on viral protein maturation. In one patient,
the p24 band on the Western blot was below the limit of
detection in all plasma samples. There was an apparent
delay in LPV activity following treatment in vivo asAIDS Research and Therapy 2005, 2:2 http://www.aidsrestherapy.com/content/2/1/2
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Western blot analyses for the HIV-1 gag proteins in patient plasma prior to and following ARV treatment Figure 2
Western blot analyses for the HIV-1 gag proteins in patient plasma prior to and following ARV treatment. 
Patient plasma was obtained at 0, 4, 8, 12, 24, 72 hours and 4 weeks following ARV treatment. Plasma was diluted with serum-
free media and then centrifuged to pellet HIV-1 particles prior to the analyses (see Fig. 1). Panel A shows the Western blot 
results on plasma samples obtained from patient A who was treated with NVP+3TC+D4T+ABV and patient B who was 
treated with LPV+NVP. Panel B shows the ratios of unprocessed p55gag to processed CA p24 in patients treated with 
NVP+3TC+D4T+ABV (patient A) or NVP+LPV (patient B, C, and D). Each bar at each time point represents analyses from a 
separate Western blot. Panel C is a plot showing the changes in CD4 cell count (cells/mm3; open squares) and viral RNA load 
in plasma (copies/ml, filled diamonds) following treated with either treatment regimen.
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Comparing the drop in viral RNA load to the increase in precursor gag protein following treatment with LPV and NVP Figure 3
Comparing the drop in viral RNA load to the increase in precursor gag protein following treatment with LPV 
and NVP. The fold increase in the p55:p24 ratio was calculated by dividing these ratios at 3 days and 4 weeks by the observed 
ratio prior to treatment (time 0) (panel A). Panel B shows the fold decrease in viral RNA load at 3 days and 4 weeks following 
LPV+NVP treatment. This calculation involved dividing the viral load at day 3 and week 4 by that at time 0.
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compared to treatment in tissue culture (Figs. 1 and 2). A
longer time was likely required to attain inhibitory con-
centrations in blood or other tissues whereas the effect of
LPV on newly produced virus particles was immediate in
tissue culture.
Nearly all antiretroviral drug-naïve patients recruited into
AACTG 5014 demonstrate a drop in viral RNA load to
undetectable levels after 8 weeks of treatment with either
regimen. This viral load decrease was associated with an
increase in CD4 cell counts. In patients B, C, and D, the
drop in viral load was likely mediated by both NVP and
LPV but the initial viral RNA load decrease (within one
week) could be more of a measure of NVP than LPV inhib-
itory activity (Fig. 2C). Within three days, PI appeared to
be blocking protease cleavage of precursor gag proteins in
the virus particles found in plasma (Fig. 2B). This ratio
increased only slightly during the next four weeks.
Because this was a pilot study on a limited number of
patients, it is difficult to ascertain what constitutes a sig-
nificant change in p55:p24. However, it appears that there
is a significant difference observed with the PI-containing
regimen at 72 hours and 4 weeks. The minimal drop in
viral load observed after three days post NVP+LPV treat-
ment (<1 log) increased from a 13- to over a 100-fold
decrease after four weeks of treatment (1.5 to 3 log
decrease; panels II, III, IV in Fig. 2C and 3A). Interestingly,
the relative decrease in viral load among these three
LPV+NVP treated patients at four weeks also appeared to
correspond to relative inhibition of protease cleavage at
only three days post treatment (Fig. 3). Patient B showed
a delayed and slower drop in viral load (at four weeks)
and a higher increase in the p55:p24 ratio (at three days)
than that observed in patient C and D (Fig. 3). A greater
increase in p55:p24 ratio in patient B reflected the very
low level of p55 detected. There was significant variation
in the p55:p24 ratio (detected by Western blot) amongst
all of the PI-naïve patients. Although difficult to test, this
variation may be related to varying ratios of infectious vir-
ion:non-infectious virus particle production in HIV-
infected individuals. These data suggest that the ratio of
p55:p24 at three days following initiation of PI treatment
may be predictive of the immediate HIV-1 inhibition by
PIs in a patient. It should be noted that without the enroll-
ment of more patients starting PI-based therapy, it is diffi-
cult to understand the relationship between the relative
increase in the p55:p24 ratios and response to therapy
except that the rapid increase in the ratio is strong indica-
tor of anti-HIV PI activity in the patient.
Conclusion
In summary HIV protease inhibitors block the processing
of p55gag and p160gag-pol precursor proteins during virus
budding or following virus release. However, the protease
inhibitor does not impede incorporation of genomic HIV-
1 RNA into the virus particle. Thus, following PI treat-
ment, viral load assays based on detection of viral RNA
measure both noninfectious, immature virus particles and
virions found in plasma. We have developed a method to
measure the anti-HIV activity of a protease inhibitor using
a simple approach. In three patients treated with
LPV+NVP, the ratio of unprocessed p55:processed p24
increased at 72 hours and over the next four weeks of
treatment. In contrast, the ratio of HIV-1 p55:p24 did not
change over the four weeks of study in patients treated
with an NNRTI-containing regimen
(NVP+3TC+D4T+ABV). This pilot study, though limited
in patient number, has provided evidence that an HIV-1
p24 Western blot can be used to immediately measure the
antiviral activity of protease inhibitors. Preliminary in
vitro data also suggests that inability of PIs to block PI-
resistant HIV-1 in patients could be assessed within 3 days
of treatment. Based on these findings we are now testing
the utility of this assay in highly PI experienced patients to
predict the success of a new PI-containing treatment regi-
men within 3 days of starting this therapy. In addition,
this study indicates that western blot is an excellent tool
for the evaluation of the activity of protease inhibitors in
vitro, and may be useful in evaluating new drugs puta-
tively active against isolates resistant to current agents, or
to evaluate the activity of different combinations of pro-
tease inhibitors using a more insightful measure than viral
infectivity.
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